Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions β€” written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Subependymal giant cell astrocytoma epidemiology and demographics

Introduction

Overview

Overview

Subependymal giant cell astrocytoma is the most common central nervous system tumor in patients with tuberous sclerosis complex. Approximately 10-20% of patients with tuberous sclerosis develop subependymal giant cell astrocytoma. It is a disease that tends to commonly affect the pediatric population with males being more affected than females.

Epidemiology and Demographics

Epidemiology and Demographics

Incidence

  • The incidence of subependymal giant cell astrocytoma is approximately 0.027 per 100,000 person-years.[1]

Prevalence

Age

  • Subependymal giant cell astrocytoma is a disease that tends to affect the pediatric, adolescent, and young adult population.[4]
  • The mean age at diagnosis is 13 years.[5]
  • It commonly presents in the first two decades of life.[6]
  • It becomes symptomatic, clinically and pathologically, between 8 to 19 years of age.[2]

Race

  • There is no racial predilection to subependymal giant cell astrocytoma.

Gender

  • Males are more commonly affected with subependymal giant cell astrocytoma than females.[2][4][7]
References

References

  1. ↑ Nguyen HS, Doan NB, Gelsomino M, Shabani S, Awad AJ, Best B; et al. (2018). “Subependymal Giant Cell Astrocytoma: A Surveillance, Epidemiology, and End Results Program-Based Analysis from 2004 to 2013”. World Neurosurg. 118: e263–e268. doi:10.1016/j.wneu.2018.06.169. PMIDΒ 29966782.
  2. ↑ 2.0 2.1 2.2 Ouyang, Taohui; Zhang, Na; Benjamin, Thomas; Wang, Long; Jiao, Jiantong; Zhao, Yiqing; Chen, Jian (2014). “Subependymal giant cell astrocytoma: current concepts, management, and future directions”. Child’s Nervous System. 30 (4): 561–570. doi:10.1007/s00381-014-2383-x. ISSNΒ 0256-7040.
  3. ↑ Roth, Jonathan; Roach, E. Steve; Bartels, Ute; JΓ³ΕΊwiak, Sergiusz; Koenig, Mary Kay; Weiner, Howard L.; Franz, David N.; Wang, Henry Z. (2013). “Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012”. Pediatric Neurology. 49 (6): 439–444. doi:10.1016/j.pediatrneurol.2013.08.017. ISSNΒ 0887-8994.
  4. ↑ 4.0 4.1 Campen CJ, Porter BE (2011). “Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update”. Curr Treat Options Neurol. 13 (4): 380–5. doi:10.1007/s11940-011-0123-z. PMCΒ 3130084. PMIDΒ 21465222.
  5. ↑ Nabbout, R; Santos, M; Rolland, Y; Delalande, O; Dulac, O; Chiron, C (1999). “Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis”. Journal of Neurology, Neurosurgery & Psychiatry. 66 (3): 370–375. doi:10.1136/jnnp.66.3.370. ISSNΒ 0022-3050.
  6. ↑ Stein JR, Reidman DA (2016). “Imaging Manifestations of a Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis”. Case Rep Radiol. 2016: 3750450. doi:10.1155/2016/3750450. PMCΒ 4752974. PMIDΒ 26942030.
  7. ↑ Sun P, Kohrman M, Liu J, Guo A, Rogerio J, Krueger D (2012). “Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis”. Curr Med Res Opin. 28 (4): 657–63. doi:10.1185/03007995.2012.658907. PMIDΒ 22375958.


Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ifeoma Odukwe, M.D. [2], Sujit Routray, M.D. [3]